Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
Kaletra is a fixed-dose combination of lopinavir and ritonavir, protease inhibitors used to treat HIV-1 infection. Ritonavir acts as a pharmacokinetic booster, increasing lopinavir concentrations to therapeutic levels. The combination is administered orally as a capsule formulation.
Product approaching loss of exclusivity with moderate competitive pressure (30), signaling potential team restructuring and transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation
Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)
Worked on KALETRA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Kaletra offers experience in mature product management, healthcare provider relationships, and patient access in a competitive therapeutic class. The LOE-approaching status provides valuable exposure to transition planning, generic competition, and cost-containment strategies critical in specialty pharma.